| Medical and Health Sciences | Lifetime | 524 | US 283 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 123 | US 50 | 99.98 |
| Medical Genetics | Lifetime | 5 | US 4 | 99.95 |
| Pulmonary and Respiratory Medicine | Lifetime | 337 | US 183 | 99.58 |
| Oncology | Lifetime | 789 | US 434 | 98.32 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 761 | US 415 | 97.99 |
| Cancer Research | Lifetime | 420 | US 227 | 97.45 |
| Clinical Neurology | Lifetime | 682 | US 302 | 96.52 |
| Medical Genetics | 2021-2025 | 1 | US 1 | 99.96 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 146 | US 47 | 99.01 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 176 | US 60 | 96.64 |
| Epidemiology | 2021-2025 | 518 | US 173 | 95.26 |
| Oncology | 2021-2025 | 392 | US 167 | 95.52 |
| Cancer Research | 2021-2025 | 162 | US 56 | 91.50 |
| Clinical Neurology | 2021-2025 | 381 | US 149 | 87.43 |
| Glioma Diagnosis and Treatment | Lifetime | 2 | US 1 | 99.97 |
| Brain Metastases and Treatment | Lifetime | 3 | US 2 | 99.95 |
| Radiomics and Machine Learning in Medical Imaging | Lifetime | 11 | US 4 | 99.89 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 30 | US 16 | 99.85 |
| Neuroblastoma Research and Treatments | Lifetime | 11 | US 9 | 99.77 |
| Histone Deacetylase Inhibitors Research | Lifetime | 13 | US 11 | 99.79 |
| Cancer Mechanisms and Therapy | Lifetime | 17 | US 11 | 99.56 |
| Meningioma and schwannoma management | Lifetime | 34 | US 27 | 99.72 |
| Cancer Genomics and Diagnostics | Lifetime | 221 | US 140 | 99.52 |
| Cancer Treatment and Pharmacology | Lifetime | 171 | US 93 | 99.46 |
| Cancer Research and Treatments | Lifetime | 155 | US 102 | 98.87 |
| Lung Cancer Research Studies | Lifetime | 232 | US 112 | 99.02 |
| Medical Imaging Techniques and Applications | Lifetime | 484 | US 216 | 98.45 |
| Protein Degradation and Inhibitors | Lifetime | 175 | US 105 | 98.60 |
| Neurofibromatosis and Schwannoma Cases | Lifetime | 113 | US 77 | 98.52 |
| Angiogenesis and VEGF in Cancer | Lifetime | 229 | US 110 | 98.49 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 803 | US 395 | 98.32 |
| MRI in cancer diagnosis | Lifetime | 341 | US 158 | 98.04 |
| Lung Cancer Treatments and Mutations | Lifetime | 956 | US 437 | 98.15 |
| Management of metastatic bone disease | Lifetime | 324 | US 167 | 96.41 |
| Cancer-related cognitive impairment studies | Lifetime | 431 | US 240 | 91.61 |
| Chromatin Remodeling and Cancer | Lifetime | 619 | US 285 | 87.55 |
| Glioma Diagnosis and Treatment | 2021-2025 | 2 | US 1 | 99.97 |
| Neuroblastoma Research and Treatments | 2021-2025 | 1 | US 1 | 99.60 |
| Brain Metastases and Treatment | 2021-2025 | 2 | US 1 | 99.90 |
| Cancer Genomics and Diagnostics | 2021-2025 | 76 | US 43 | 99.33 |
| Meningioma and schwannoma management | 2021-2025 | 17 | US 12 | 99.21 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 38 | US 11 | 98.34 |
| Radiomics and Machine Learning in Medical Imaging | 2021-2025 | 101 | US 16 | 98.88 |
| Cancer Research and Treatments | 2021-2025 | 23 | US 5 | 97.89 |
| Medical Imaging Techniques and Applications | 2021-2025 | 152 | US 43 | 97.34 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 628 | US 236 | 97.61 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 97 | US 46 | 93.88 |
| Lung Cancer Research Studies | 2021-2025 | 287 | US 93 | 96.48 |
| Cancer Treatment and Pharmacology | 2021-2025 | 495 | US 180 | 90.70 |
| Statistical Methods in Clinical Trials | 2021-2025 | 186 | US 77 | 88.96 |
| Cancer Mechanisms and Therapy | 2021-2025 | 323 | US 49 | 85.18 |
| Cancer-related cognitive impairment studies | 2021-2025 | 279 | US 127 | 84.11 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 895 | US 212 | 86.06 |
| Chromatin Remodeling and Cancer | 2021-2025 | 224 | US 91 | 78.03 |
| Neurofibromatosis and Schwannoma Cases | 2021-2025 | 429 | US 166 | 82.04 |
| Melanoma and MAPK Pathways | 2021-2025 | 566 | US 191 | 76.93 |
| Mathematical Biology Tumor Growth | 2021-2025 | 749 | US 114 | 55.83 |
